Insulin icodec

Phase 3

Novo Nordisk

Insulin icodec is one of 7 therapeutic programs targeting Diabetes Mellitus, Type 1. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetes Mellitus, Type 1Recruiting

Diabetes, Type 2Completed

Diabetes Mellitus, Type 1Phase 3

Recruiting

Diabetes, Type 2Phase 3

Completed

Competition

Competitive Landscape

10 competitors in Diabetes Mellitus, Type 1

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Phase 3

2 2

VX-880

Vertex Pharmaceuticals

Phase 3

1 3

Bacillus Calmette-Guérin

Bristol-Myers Squibb

Phase 2

1 4

Insulin icodec

Novo Nordisk

Phase 3

3 5

Lyumjev U-100 Insulin

SStanford University

Phase 1

1 6

Diluted Humalog U-200 Insulin

SStanford University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Active, not recruiting

Diabetes Mellitus, Type 1

NCT07160816

Phase 3Recruiting

Diabetes Mellitus, Type 1

NCT07076199

Q4 2027

Not yet recruiting

Diabetes Mellitus, Type 2

NCT07658417

Q1 2028

Recruiting

Diabetes Mellitus, Type 1

NCT06807190

Clinical

Trials by Indication[1]

Diabetes Mellitus, Type 13 trials

A Multi-centre, Prospective, Open Label, Non-interventional, Single-armed, 52 Weeks Post-marketing Study to Investigate Safety and Clinical Parameters of Awiqli Once Weekly in Patients With Diabetes Mellitus Under Real-world Clinical Practice Setting in Japan

Recruiting· Novo Nordisk logo

Novo Nordisk··NCT06807190·630 enrolled

A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT07076199·877 enrolled

A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Use of Insulin Icodec in People Living With Type 1 Diabetes

Active, not recruiting· Novo Nordisk logo

Novo Nordisk··NCT07160816·245 enrolled

Diabetes, Type 21 trial

A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec When Switching From Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06340854·412 enrolled

Diabetes Mellitus, Type 21 trial

A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Switch From Daily Basal Insulin to Insulin Icodec in People Living With Type 2 Diabetes in China

Not yet recruiting· Novo Nordisk logo

Novo Nordisk··NCT07658417·216 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Insulin icodec. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Insulin icodec. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Novo Nordisk

Insulin icodec

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Diabetes Mellitus, Type 13 trials

Diabetes, Type 21 trial

Diabetes Mellitus, Type 21 trial

References

Drug Info

Quick Facts

Related News